PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (IMMUNE SUPPORT)
DRUG NAME: LARAZOTIDE

• FDA Safety Data Sheet not available (experimental peptide).

• Slifer ZM. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. Am J Physiol Gastrointest Liver Physiol. 2021 [PubMed Link]

• Kulkarni A. Current pharmacological approaches and potential future therapies for Celiac disease. Eur J Pharmacol. 2021 [PubMed Link]

• Troisi J. The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases. Curr Med Chem. 2021 [PubMed Link]

• Hoilat GJ. Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2022 [PubMed Link]

• Glinka DM. The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis. JID Innov. 2025 [PubMed Link]

• Slifer ZM. Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions. PLoS One. 2021 [PubMed Link]

• Armandi A. Tight junction regulation in celiac disease: role of larazotide acetate. Minerva Gastroenterol (Torino). 2022 [PubMed Link]

• Enomoto H. In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model. PLoS One. 2021 [PubMed Link]

• D'heedene M. Celiac disease: Hope for new treatments beyond a gluten-free diet. Clin Nutr. 2024 [PubMed Link]